Trigemina

About:

Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.

Top Investors: Aurus

Description:

Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.

Total Funding Amount:

$27.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Moraga, California, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)trigemina.com

Founders:

David C Yeomans, Martin Angst, William Frey II

Number of Employees:

11-50

Last Funding Date:

2017-07-15

IPO Status:

Private

Industries: